Alnylam Pharmaceuticals (ALNY) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Alnylam Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$3.71B

Latest Revenue (Q)

$1.25B

Main Segment (Y)

GIVLAARI

Main Geography (Y)

UNITED STATES

Alnylam Pharmaceuticals Revenue by Period

Alnylam Pharmaceuticals Revenue by Year

Date	Revenue	Change
2025-12-31	$3.71B	65.19%
2024-12-31	$2.25B	22.97%
2023-12-31	$1.83B	76.23%
2022-12-31	$1.04B	22.88%
2021-12-31	$844.29M	71.31%
2020-12-31	$492.85M	124.28%
2019-12-31	$219.75M	193.36%
2018-12-31	$74.91M	-16.69%
2017-12-31	$89.91M	90.66%
2016-12-31	$47.16M	14.75%
2015-12-31	$41.10M	-18.72%
2014-12-31	$50.56M	7.20%
2013-12-31	$47.17M	-29.31%
2012-12-31	$66.72M	-19.37%
2011-12-31	$82.76M	-17.28%
2010-12-31	$100.04M	-0.49%
2009-12-31	$100.53M	4.54%
2008-12-31	$96.16M	88.94%
2007-12-31	$50.90M	89.00%
2006-12-31	$26.93M	371.13%
2005-12-31	$5.72M	33.61%
2004-12-31	$4.28M	2330.68%
2003-12-31	$176.00K	100.00%
2002-12-31	-	-

Alnylam Pharmaceuticals generated $3.71B in revenue during NA 2025, up 65.19% compared to the previous quarter, and up 753.56% compared to the same period a year ago.

Alnylam Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2025-09-30	$1.25B	61.44%
2025-06-30	$773.69M	30.21%
2025-03-31	$594.19M	0.17%
2024-12-31	$593.17M	18.42%
2024-09-30	$500.92M	-24.08%
2024-06-30	$659.83M	33.48%
2024-03-31	$494.33M	12.42%
2023-12-31	$439.72M	-41.41%
2023-09-30	$750.53M	135.46%
2023-06-30	$318.75M	-0.17%
2023-03-31	$319.29M	-4.70%
2022-12-31	$335.04M	26.76%
2022-09-30	$264.31M	17.56%
2022-06-30	$224.82M	5.42%
2022-03-31	$213.26M	-17.51%
2021-12-31	$258.54M	37.79%
2021-09-30	$187.63M	-14.93%
2021-06-30	$220.55M	24.21%
2021-03-31	$177.57M	8.56%
2020-12-31	$163.56M	29.96%
2020-09-30	$125.85M	21.06%
2020-06-30	$103.96M	4.51%
2020-03-31	$99.48M	38.78%
2019-12-31	$71.68M	2.31%
2019-09-30	$70.06M	56.69%
2019-06-30	$44.71M	34.30%
2019-03-31	$33.29M	58.29%
2018-12-31	$21.03M	916.58%
2018-09-30	$2.07M	-93.08%
2018-06-30	$29.91M	36.57%
2018-03-31	$21.90M	-42.26%
2017-12-31	$37.92M	121.83%
2017-09-30	$17.10M	7.31%
2017-06-30	$15.93M	-15.97%
2017-03-31	$18.96M	8.63%
2016-12-31	$17.45M	27.86%
2016-09-30	$13.65M	56.75%
2016-06-30	$8.71M	18.57%
2016-03-31	$7.34M	-2.73%
2015-12-31	$7.55M	19.40%
2015-09-30	$6.32M	-27.18%
2015-06-30	$8.69M	-53.15%
2015-03-31	$18.54M	-22.82%
2014-12-31	$24.02M	118.91%
2014-09-30	$10.97M	50.40%
2014-06-30	$7.29M	-11.84%
2014-03-31	$8.28M	-23.71%
2013-12-31	$10.85M	20.64%
2013-09-30	$8.99M	3.50%
2013-06-30	$8.69M	-53.40%
2013-03-31	$18.64M	119.45%
2012-12-31	$8.49M	-49.31%
2012-09-30	$16.76M	-19.75%
2012-06-30	$20.88M	1.44%
2012-03-31	$20.59M	0.65%
2011-12-31	$20.45M	-1.62%
2011-09-30	$20.79M	0.86%
2011-06-30	$20.61M	-1.35%
2011-03-31	$20.90M	-1.39%
2010-12-31	$21.19M	-23.41%
2010-09-30	$27.67M	3.95%
2010-06-30	$26.62M	8.36%
2010-03-31	$24.56M	-7.74%
2009-12-31	$26.63M	9.80%
2009-09-30	$24.25M	-1.43%
2009-06-30	$24.60M	-1.82%
2009-03-31	$25.06M	2.68%
2008-12-31	$24.40M	-5.17%
2008-09-30	$25.73M	7.98%
2008-06-30	$23.83M	7.39%
2008-03-31	$22.19M	21.72%
2007-12-31	$18.23M	-

Alnylam Pharmaceuticals generated $1.25B in revenue during Q3 2025, up 61.44% compared to the previous quarter, and up 189.30% compared to the same period a year ago.

Alnylam Pharmaceuticals Revenue Breakdown

Alnylam Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
GIVLAARI	$308.49M	$255.87M	$219.25M	-	-
ONPATTRO	$172.79M	-	-	-	-
Product	-	$1.65B	$1.24B	$894.33M	$662.14M
Royalty	-	-	-	$8.18M	$1.20M

Alnylam Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: GIVLAARI (64.10%), and ONPATTRO (35.90%).

Quarterly Revenue by Product

Product/Service	Dec 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
ONPATTRO	$70.76M	$52.54M	$49.49M	$50.29M	$77.24M	$69.22M	$81.59M	-	-	-	-	-	-	-	-	-	-	-	-	-
GIVLAARI	$160.67M	$80.85M	$66.97M	$64.64M	$71.04M	$62.13M	$58.06M	$165.10M	$54.15M	-	-	-	-	-	-	-	-	-	-	-
Product	-	$672.21M	$468.54M	$450.83M	$420.15M	$410.09M	$365.16M	$346.29M	$313.15M	$305.70M	$276.33M	$261.68M	$232.27M	$213.51M	$186.87M	$198.51M	$167.04M	$160.81M	$135.77M	$112.84M
Royalty	-	-	-	-	-	-	-	-	-	$7.21M	$6.50M	$2.71M	$2.74M	$2.28M	$442.00K	$396.00K	$453.00K	$347.00K	-	-

Alnylam Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: GIVLAARI (69.42%), and ONPATTRO (30.58%).

Alnylam Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Non-US Or Europe	$176.72M	$104.40M	$75.77M	$4.17M	$1.76M
UNITED STATES	$1.73B	$630.61M	$411.17M	$27.70M	$18.88M
Europe	$405.90M	$235.44M	$210.92M	$37.91M	$38.95M

Alnylam Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (74.82%), Europe (17.54%), and Non-US Or Europe (7.64%).

Quarterly Revenue by Country

Country	Dec 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Non-US Or Europe	$107.04M	$37.74M	$31.94M	$33.45M	$24.79M	$24.89M	$21.27M	$55.02M	$15.76M	$3.20M	$1.79M	$2.23M	$698.00K	$223.00K	$1.02M	$24.67M	$18.05M	$16.54M	$11.83M	$14.19M
Europe	$232.94M	$92.87M	$80.09M	$68.85M	$65.14M	$56.76M	$44.69M	$135.02M	$50.37M	$12.22M	$13.31M	$12.82M	$9.35M	$7.59M	$8.16M	$11.72M	$9.66M	$9.83M	$7.74M	$33.09M
UNITED STATES	$1.17B	$361.35M	$197.96M	$183.25M	$168.66M	$148.46M	$130.24M	$279.81M	$113.51M	$8.79M	$9.06M	$8.78M	$6.38M	$7.12M	$5.41M	$5.72M	$5.24M	$6.51M	$1.41M	$43.08M

Alnylam Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (77.51%), Europe (15.41%), and Non-US Or Europe (7.08%).

Alnylam Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
COR	Cencora	$321.33B	$85.93B
CI	Cigna	$274.95B	$69.75B
CAH	Cardinal Health	$222.58B	$65.44B
BDX	Becton, Dickinson and	$21.84B	$5.25B
REGN	Regeneron Pharmaceuticals	$14.34B	$3.75B
ZTS	Zoetis	$9.47B	$2.40B
EW	Edwards Lifesciences	$6.07B	$1.55B
IDXX	IDEXX Laboratories	$4.30B	$1.11B
ALNY	Alnylam Pharmaceuticals	$3.71B	$1.25B
VEEV	Veeva Systems	$2.75B	$811.24M
ARGX	argenx SE	$1.23B	$401.00M

ALNY Revenue FAQ

What is Alnylam Pharmaceuticals’s yearly revenue?

Alnylam Pharmaceuticals's yearly revenue for 2025 was $3.71B, representing an increase of 65.19% compared to 2024. The company's yearly revenue for 2024 was $2.25B, representing an increase of 22.97% compared to 2023. ALNY's yearly revenue for 2023 was $1.83B, representing an increase of 76.23% compared to 2022.

What is Alnylam Pharmaceuticals’s quarterly revenue?

Alnylam Pharmaceuticals's quarterly revenue for Q3 2025 was $1.25B, a 61.44% increase from the previous quarter (Q2 2025), and a 149.35% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $773.69M, a 30.21% increase from the previous quarter (Q1 2025), and a 17.26% increase year-over-year (Q2 2024). ALNY's quarterly revenue for Q1 2025 was $594.19M, a 0.17% increase from the previous quarter (Q4 2024), and a 20.20% increase year-over-year (Q1 2024).

What is Alnylam Pharmaceuticals’s revenue growth rate?

Alnylam Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 103.14%, and for the last 5 years (2021-2025) was 339.89%.

What are Alnylam Pharmaceuticals’s revenue streams?

Alnylam Pharmaceuticals's revenue streams in c 25 are GIVLAARI, and ONPATTRO. GIVLAARI generated $308.49M in revenue, accounting 64.10% of the company's total revenue, up 20.56% year-over-year. ONPATTRO generated $172.79M in revenue, accounting 35.90% of the company's total revenue

What is Alnylam Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Alnylam Pharmaceuticals was GIVLAARI. This segment made a revenue of $308.49M, representing 64.10% of the company's total revenue.